SVA - シノバック・バイオテック （Sinovac Biotech Ltd.）

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, reminds investors that a class action lawsuit has been filed against Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA) in the United States District Court for the Southern District of New York on behalf of all persons and entities who purchased or otherwise acquired Sinovac securities between April 11, 2016 and February 22, 2019, both dates inclusive (the “Class Period”

Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against 1Globe Capital LLC (“1Globe”) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA) stock between April 11, 2016, and February 22, 2019 (the “Class

NEW YORK, Oct. 4, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds sellers of the stock of Sinovac Biotech Ltd. (NASDAQ: SVA) between April 11, 2016 and February 22, 2019, both dates inclusive (the "Class Period"), of the October 17, 2022 lead plaintiff…

Authorities confirm Post report, with health minister Lo Chung-mau and scientific committee to review application to make available BioNTech jab for youngsters.

NEW YORK, Sept. 14, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds sellers of the stock of Sinovac Biotech Ltd. (NASDAQ: SVA) between April 11, 2016 and February 22, 2019, both dates inclusive (the "Class Period"), of the October 17, 2022 lead…

Sinovac Biotech press release (SVA): FY GAAP EPS of $74.27.Revenue of $19.4B (+3699.5% Y/Y).Non-GAAP adjusted EBITDA was $17.6B in 2021, compared to $229.9M in the prior year.As…

BEIJING, China--(BUSINESS WIRE)--Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, has filed its 2021 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2021. The Company also reported its unaudited financial for the second half and full year ended December 31, 2021. Second Half and Full Year 2021 Financial Summary Sales for the six months ended December 31, 2021 we

Two homegrown Omicron-specific COVID-19 vaccine candidates developed by Sinopharm and Sinovac Biotech have been approved for clinical trials by China''s top drug regulator, the two companies said on Tuesday.

Sinovac Biotech''s (SVA) Omicron-specific vaccine was approved for clinical trials in Hong Kong.Sinovac, a unit of Sinopharm Group (SHTDF) (SHTDY), said preclinical studies showed that…

Sinovac Biotech (SVA) said a study in Hong Kong suggested that three shots of its COVID-19 vaccine CoronaVac offered ~98% protection against death or severe illness in people over 60…

Analysis reveals Pfizer-BioNTech vaccine more effective.

Futures Ramp Above 4,700 On Growing Omicron Optimism If you had gone to bed on Thanksgiving after eating a little too much tryptophan and only woken up today, roughly one month later, you would have completely avoided a rollercoaster move in global markets, and much of the omicron panic, with the S&P now trading precisely where it was the night before scattered reports of Omicron in South Africa sparked a global selloff. As of 730am, e-mini S&P futures were trading at exactly 4,700, up 14 points or 0.3% - and once again less than 1% from all time highs - on rising hopes the omicron variant wont impact global growth even as officials remain cautious about its spread, after studies showed its less severe than other strains; Dow Jones futures also rose 0.3% while Nasdaq 100 futures were 0.2% higher. US Treasury yields rose, the 10Y trading at 1.475%, while the USD index traded flat. The pound rose as traders stepped up bets on a Bank of England rate hike. Soaraing European natural gas prices plunged more than 20% as this years rally attracted a flotilla of U.S. cargoes, helping offset lower flows from Russia.

A Chinese study has revealed that the vaccine made by Chinas Sinovac Biotech fails to provide adequate protection against the Omicron variant of Covid-19 even after a booster shot has been administered. Read Full Article at RT.com

Three doses of the COVID-19 vaccine developed by Chinese company Sinovac Biotech fail to fully protect against the Omicron coronavirus variant, according to the latest study published on Thursday. Ho…

That is a major blow to China, whose population majority have been vaccinated with Sinovac